Related Experiment Video
Updated: May 15, 2025
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
9.2K
US Drug Pricing Patterns Before Loss of Exclusivity
Ching-Hsuan Lin1, Jonathan D Campbell2, James Motyka2
1Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
Summary
Drug prices often decrease after launch, contrary to common assumptions in cost-effectiveness analyses. This study models these dynamic price changes to improve economic projections for branded drugs.
Area of Science:
- Health Economics
- Pharmaceutical Policy
- Pharmacoeconomics
Background:
- Cost-effectiveness analyses (CEAs) often assume static drug pricing post-launch.
- This assumption can lead to inaccurate economic projections due to typical price fluctuations.
- Limited empirical data on drug price dynamics hinders the incorporation of realistic pricing into CEAs.
Purpose of the Study:
- To characterize inflation-adjusted price changes for branded drugs after launch and before market exclusivity loss.
- To develop and apply regression models for projecting drug price trajectories.
- To identify factors influencing drug price changes over their life cycle.
Main Methods:
- Analysis of inflation-adjusted net price data for 32 high-spending US brand-name drugs.
- Development of ordinary least squares and linear mixed-effects regression models.
- Identification and selection of influencing factors based on literature review and statistical criteria.
Main Results:
- Average inflation-adjusted annual drug price change was -4.7% (median: -2.4%).
- Models predicted price declines across most drug types, with exceptions for Medicare-protected class drugs.
- Price change rates tended to moderate over time since drug launch.
Conclusions:
- Inflation-adjusted prices for large-market branded drugs commonly decline post-launch and pre-exclusivity loss.
- Empirical modeling of dynamic pricing enhances the accuracy of CEAs.
- Incorporating observable drug characteristics can refine economic projections.
Related Concept Videos
01:17Drug Nomenclature
1.5K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.5K
01:02Prescription, Nonprescription and Orphan Drugs
665
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
665
01:16Bioequivalence: Overview
890
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
890
01:25Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
33
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
33
01:22Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
92
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
92